1. Besses C, Alvarez-Larrán A (2016) How to treat essential thrombocythemia and polycythemia vera. Clin Lymphoma Myeloma Leuk 16(Suppl):S114–S123. https://doi.org/10.1016/j.clml.2016.02.029
2. European Medicines Agency (EMA) (2009) Xagrid (anagrelide). An overview of Xagrid and why it is authorised in the EU. Retrieved 15 May 2022, from https://www.ema.europa.eu/en/documents/overview/xagrid-epar-medicine-overview_en.pdf
3. Mazzucconi MG, Redi R, Bernasconi S, Bizzoni L, Dragoni F, Latagliata R, Santoro C, Mandelli F (2004) A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica 89(11):1306–1313
4. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; ANAHYDRET Study Group (2013) Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 121(10):1720–1728. https://doi.org/10.1182/blood-2012-07-443770
5. European Medicines Agency (EMA) (2022) Xagrid (anagrelide hydrochloride): Risk of thrombosis including cerebral infarction upon abrupt treatment discontinuation. Retrieved 15 May 2022, from https://www.ema.europa.eu/en/medicines/dhpc/xagrid-anagrelide-hydrochloride-risk-thrombosis-including-cerebral-infarction-upon-abrupt-treatment